Información del producto
- ON-01910
Rigosertib is a small molecule that inhibits the activity of the protein ErbB2. It has been shown to induce reactive oxygen species (ROS) and inhibit tumor growth in preclinical models. Rigosertib is being investigated as an investigational agent for cancer therapeutics. It has been shown to be well tolerated in animals and humans with minimal toxicity. Rigosertib prevents cell-cell interactions by binding to EGFR, which may have therapeutic potential in squamous cell carcinomas and melanoma cells. Rigosertib also inhibits the activity of tyrosine kinases and may be useful for treatment of cancers that are resistant to other therapies, such as coumarin derivatives, which are used in combination with chemotherapy for treatment of acute myeloid leukemia. RIGSERTIB blocks tumor growth by inducing apoptosis through activation of caspase-3 and caspase-7 pathways, which causes DNA fragmentation, nuclear condensation, and cleavage of poly
Propiedades químicas
Consulta técnica sobre: 3D-FR137713 Rigosertib
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
